Rossari Biotech Ltd
Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India. [1]
Their 3 main product categories are [2]:
- Home, personal care, and performance chemicals
- Textile specialty chemical
- Animal health and nutrition
The company has two R&D facilities, one at Silvassa manufacturing facility and a research lab at IIT Bombay. [3]
- Market Cap ₹ 2,793 Cr.
- Current Price ₹ 504
- High / Low ₹ 768 / 373
- Stock P/E 20.3
- Book Value ₹ 226
- Dividend Yield 0.10 %
- ROCE 15.8 %
- ROE 12.2 %
- Face Value ₹ 2.00
Pros
Cons
- Company has a low return on equity of 12.6% over last 3 years.
- Dividend payout has been low at 2.24% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE Commodities BSE 1000
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 516 | 600 | 709 | 1,483 | 1,656 | 1,831 | 2,080 | 2,291 | |
| 438 | 495 | 586 | 1,299 | 1,433 | 1,581 | 1,815 | 2,013 | |
| Operating Profit | 78 | 105 | 124 | 184 | 223 | 250 | 265 | 278 |
| OPM % | 15% | 17% | 17% | 12% | 13% | 14% | 13% | 12% |
| 1 | 4 | 9 | 13 | 6 | 8 | 5 | 7 | |
| Interest | 3 | 4 | 3 | 13 | 22 | 19 | 18 | 25 |
| Depreciation | 12 | 17 | 23 | 48 | 63 | 60 | 67 | 74 |
| Profit before tax | 63 | 88 | 107 | 136 | 144 | 178 | 185 | 186 |
| Tax % | 28% | 26% | 25% | 28% | 26% | 26% | 26% | |
| 46 | 65 | 80 | 98 | 107 | 131 | 136 | 138 | |
| EPS in Rs | 103.82 | 12.86 | 15.45 | 17.74 | 19.45 | 23.66 | 24.63 | 24.87 |
| Dividend Payout % | 0% | 4% | 3% | 3% | 3% | 2% | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 12% |
| TTM: | 16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 12% |
| TTM: | 1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -14% |
| 3 Years: | -10% |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 13% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 10 | 10 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 119 | 277 | 398 | 794 | 904 | 1,037 | 1,174 | 1,240 |
| 8 | 67 | 0 | 8 | 74 | 119 | 218 | 353 | |
| 118 | 118 | 152 | 442 | 375 | 401 | 482 | 484 | |
| Total Liabilities | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,088 |
| 74 | 94 | 181 | 607 | 585 | 578 | 598 | 630 | |
| CWIP | 3 | 22 | 0 | 1 | 16 | 47 | 140 | 247 |
| Investments | 0 | 18 | 0 | 36 | 51 | 63 | 84 | 20 |
| 173 | 338 | 379 | 611 | 712 | 880 | 1,063 | 1,190 | |
| Total Assets | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,088 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 71 | 57 | 48 | 29 | 152 | 43 | 137 | |
| -37 | -190 | -37 | -299 | -181 | -103 | -183 | |
| -29 | 157 | -25 | 292 | 61 | 16 | 65 | |
| Net Cash Flow | 5 | 23 | -14 | 22 | 32 | -44 | 19 |
| Free Cash Flow | 27 | -19 | -8 | -7 | 120 | -83 | -21 |
| CFO/OP | 118% | 74% | 64% | 43% | 89% | 39% | 74% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 57 | 74 | 75 | 78 | 85 | 83 |
| Inventory Days | 59 | 57 | 75 | 63 | 59 | 80 | 90 |
| Days Payable | 114 | 95 | 104 | 61 | 56 | 62 | 73 |
| Cash Conversion Cycle | 6 | 19 | 46 | 76 | 80 | 103 | 101 |
| Working Capital Days | 23 | 22 | 60 | 62 | 49 | 70 | 69 |
| ROCE % | 38% | 29% | 24% | 18% | 18% | 16% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Consolidated Installed Manufacturing Capacity MTPA |
|
|||||||||
| Capacity Utilization (Group/Consolidated) % |
||||||||||
| Number of Employees (Total Workforce) Number |
||||||||||
| Export Share of Revenue % |
||||||||||
| Number of Distributors Number |
||||||||||
| Number of Products in Portfolio Number |
||||||||||
| R&D Spend INR Million |
||||||||||
| Core B2B Segment Volume Growth (YoY) % |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Audited Financial Statements And Financial Results (Standalone And Consolidated) For The Quarter And Financial Year Ended March 31, 2026 And Recommendation Of Final Dividend, If Any.
7h - Board meeting on April 27, 2026 to approve FY26 audited results and consider final dividend.
-
Announcement Under Regulation 30 Of SEBI (LODR), Regulation 2015.
3 Apr - Unitop Chemicals to sell Saki Naka office premises for about Rs. 10 crore by Q2 FY27.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
3 Apr - Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
31 Mar - Unitop commissioned remaining 15,000 MTPA ethoxylation capacity; total 66,000 MTPA effective March 31, 2026.
- Closure of Trading Window 25 Mar
Annual reports
Concalls
-
Jan 2026Transcript PPT REC
-
Oct 2025Transcript PPT REC
-
Jul 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Oct 2021TranscriptAI SummaryPPT
-
Aug 2021Transcript PPT
-
Jul 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Oct 2020Transcript PPT
-
Aug 2020Transcript PPT
Product Segments
The company is one of India’s leading specialty chemicals manufacturer offering 4,280+ products across 3 verticals: [1]